Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

Rhea-AI Summary

Theravance Biopharma, Inc. (NASDAQ: TBPH) will announce its third quarter 2022 financial results and provide a business update after market close on November 7, 2022. A conference call and webcast will follow at 5:00 pm ET. The company focuses on delivering Medicines that Make a Difference and has developed the FDA-approved YUPELRI inhalation solution for COPD patients. Investors can listen to the live call via Theravance's website and access a replay for 30 days post-event.

Positive

• Theravance's focus on significant unmet patient needs through its drug development pipeline.
• The upcoming financial results announcement may provide insights into future growth prospects.

Negative

• None.

DUBLIN, Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Presentations and Events.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through December 7, 2022.

About Theravance Biopharma

Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact: Andrew Hindman
Chief Financial Officer
investor.relations@theravance.com
650-808-4145

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2022-financial-results-on-november-7-2022-301663149.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma report its Q3 2022 financial results?

Theravance Biopharma will report its Q3 2022 financial results on November 7, 2022.

What time is the Theravance Biopharma conference call scheduled?

The conference call is scheduled for 5:00 pm ET on November 7, 2022.

How can I listen to the Theravance Biopharma conference call?

You can listen to the conference call live via Theravance's website or by pre-registering for the call.

What product has Theravance Biopharma developed for COPD?

Theravance Biopharma has developed the FDA-approved YUPELRI inhalation solution for COPD patients.

Will there be a replay of the Theravance Biopharma conference call?

Yes, a replay of the conference call will be available on Theravance Biopharma's website for 30 days.